News

IO Biotech to Present at Upcoming Healthcare Conferences

IO Biotech to Present at Upcoming Healthcare Conferences

IO Biotech to Participate in Upcoming Investor Conferences

IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company focused on developing innovative immune-modulating therapeutic cancer vaccines using the T-win platform, has announced that its senior management team will be participating in several upcoming investor conferences. These events will provide valuable insights into the company's current projects and future prospects.

Conference Details

At the Morgan Stanley 22nd Annual Global Healthcare Conference, Dr. Mai-Britt Zocca, the CEO of IO Biotech, will take part in a fireside chat on September 4, 2024, at 5:35 pm ET. This conference presents a significant opportunity for IO Biotech to engage with potential investors and share updates on the ongoing developments of their therapeutic offerings.

Participation in the H.C. Wainwright Conference

Following that, Amy Sullivan, the CFO of IO Biotech, will present the company’s strategic initiatives at the H.C. Wainwright 26th Annual Global Investment Conference on September 9, 2024, at 10:30 am ET. This presentation aims to highlight the progress of IO Biotech's pipeline and its innovative approaches to cancer treatment.

Webcast Access

For those interested, a live webcast of these presentations will be available on IO Biotech's official website, allowing remote engagement with the content. After the events, the recordings will be accessible for about 90 days, enabling broader audience participation.

About IO102-IO103

IO102-IO103 is an experimental cancer vaccine designed to activate the immune system against both tumor cells and the immunosuppressive cells that hinder effective immune responses within the tumor microenvironment (TME). This pioneering therapy seeks to enhance T cell activation against indoleamine 2,3-dioxygenase (IDO) positive and programmed death-ligand 1 (PD-L1) positive cells, which are crucial targets in cancer therapy.

Clinical Trials and Collaborations

The clinical trials for IO102-IO103 are currently in critical phases. The company is conducting a Phase 3 trial (NCT05155254) that compares the vaccine in combination with pembrolizumab to pembrolizumab alone in patients with advanced melanoma. Additionally, a Phase 2 basket trial (NCT05077709) is underway to assess its effectiveness as a first-line treatment for various solid tumors, along with another Phase 2 study (NCT05280314) focusing on neo-adjuvant/adjuvant treatments. These studies are sponsored by IO Biotech in collaboration with Merck, which is providing pembrolizumab for the trials.

About IO Biotech

IO Biotech is an innovative clinical-stage biopharmaceutical company dedicated to developing immune-modulating cancer therapies. Their T-win platform offers a novel approach to cancer vaccine technology, leveraging the body’s immune response to target tumor-supportive cells. IO Biotech is advancing its lead candidate, IO102-IO103, through clinical trials while also assessing additional candidates at the preclinical stage.

Based on encouraging data from Phase 1/2 trials for metastatic melanoma, IO102-IO103 has been granted breakthrough therapy designation by the US Food and Drug Administration, enhancing its potential impact in the oncology field. IO Biotech operates globally, with its headquarters in Copenhagen and a significant presence in New York.

Contact Information

Investors
Maryann Cimino, Director of Investor Relations
IO Biotech, Inc.
617-710-7305
Email: mci@iobiotech.com

Media
Julie Funesti
Salutem
917-498-1967
Email: Julie.Funesti@salutemcomms.com

Frequently Asked Questions

What is the focus of IO Biotech?

IO Biotech specializes in developing immune-modulating therapeutic cancer vaccines.

When will IO Biotech present at investor conferences?

IO Biotech will participate in the Morgan Stanley Conference on September 4, 2024, and the H.C. Wainwright Conference on September 9, 2024.

How can I access the presentations from IO Biotech?

The webcast of the presentations will be available on IO Biotech's website for 90 days following the events.

What is IO102-IO103?

IO102-IO103 is an investigational therapeutic cancer vaccine targeting tumor cells and immune-suppressive cells in the tumor microenvironment.

Who are IO Biotech's collaborators for clinical trials?

IO Biotech conducts its clinical trials in collaboration with Merck, which supplies pembrolizumab for ongoing studies.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Testing Grounds: Navigating PRN Test Insights

Updated Category News Views 0

Deciphering the PRN Tester Repetition Today we're staring at what feels like déjà vu—a simple PR test peppered with the classic sentence about a fox and a dog. It's like someone left the 'repeat' function stuck on during a slow day at the office. But hey, let’s dig in. Is there something more behind this repetitive text, or are we grumbling at a wall? Unpacking the...

Continue Reading
Halloween 2026: Gemmy's Animatronics Add Thrills

Updated Category News Views 2

Halloween's New Twist with Gemmy's Animatronics Well, just when you thought Halloween couldn't get any more over the top, here comes Gemmy with their 3-foot tall animatronic characters ready to give your trick-or-treat scene that extra jolt. These aren't just any run-of-the-mill decorations. Nope, they come with a twist—an industrial-strength twist of scares and sweets...

Continue Reading
Bybit Enhances BTC Staking Yields Amid Crypto Fluctuations

Updated Category News Views 2

An Uptick in BTC Staking Yields Seems like Bybit's got a trick up their sleeve with their latest move. They've hiked BTC staking yields from a static 0.8% up to a more attractive 1.2%. Now, if you're parked with Bitcoin in this dicey market, that's a substantial 50% leap upwards. When you think about those dreamy numbers traders like me fantasize about, it’s a juicy...

Continue Reading
Chris Auffenberg Buick: 1.9% APR Drives New Deals

Updated Category News Views 3

New Financing Options in Carbondale In a world where financing a car sometimes feels like predicting the weather—unreliable and erratic—Chris Auffenberg Buick is turning the tables down in Carbondale with a refreshing approach. They're trotting out a 1.9% APR financing option for those Buick lovers who qualify, all through GM Financial. It's the kind of deal that...

Continue Reading
Parents Champion Meta's Online Safety Agreement

Updated Category News Views 5

Any old-timer in the market game will tell you this: safeguarding the next generation runs deeper than just chasing profits. A recent poll by the Coalition to Empower our Future reveals something that ain’t too surprising if you’ve been paying attention. Parents all over the nation are nodding along to Meta’s new move to bolster online protections for younger folks....

Continue Reading
Pudu Robotics Showcases Expansive Portfolio at IFA 2026

Updated Category News Views 1

Robotics in the Spotlight: Pudu's Grand European Entry Well, you don't see this every day—Pudu Robotics, a name riding high in the robotics sphere, is strutting its stuff over at IFA 2026 in Berlin. This ain't just a teaser, folks. They're unloading the whole toolkit, diving head-first into the European market. From gears turning in service delivery bots to industrial...

Continue Reading
Patented Foodservice Firm's $1.6M Sale: High ROI Potential

Updated Category News Views 0

Cooking Up High Margins and Rapid Growth You don’t stumble on opportunities like this every day. A foodservice company out there is posting some mouth-watering numbers, and it’s shaking up the M&A scene. This one’s got patents holding up its brand like a culinary force field, and it’s now on the auction block for a cool $1.6 million. And the numbers? Well, they...

Continue Reading
Vobile Teams Up with UNN for AI Factories in Brunei

Updated Category News Views 4

Delving into Vobile's Latest Strategic Move Vobile, a heavyweight in digital content protection based out of Santa Clara, California, has hit the headlines with a new venture. They've inked a strategic cooperation and commercial agreements with Unified National Networks (UNN) of Brunei Darussalam to construct AI factories. This ain't your run-of-the-mill news, folks. It's...

Continue Reading
Freeport-McMoRan Hit with Legal Probe: What's Next?

Updated Category News Views 4

Investigating the Movers and Shakers at Freeport When legal hawks like Kahn Swick & Foti, LLC sink their teeth into something, you can bet it's not just to nibble. These folks have jumped headfirst into probing Freeport-McMoRan Inc. (NYSE:FCX), ready to dismantle any smoke screens that might have been thrown up after the unfortunate Grasberg Block Cave mine incident. The...

Continue Reading
AEON's AI-Powered Agentic Checkout: A Game Changer?

Updated Category News Views 5

Cracking the Future: AEON Introduces Agentic Checkout There's a new sheriff in the AI economy: AEON, throwing its hat in the ring with the debut of Agentic Checkout. Now if you think we're just talking about basic automation here, think again. This thing's got its own AI Card that transforms your shopping commands into planned purchases. Think of it as handing over your...

Continue Reading

Top 5 Most Recently Viewed Articles

Transform Your Investment: The Growth of SPS Commerce Over Time

Updated Category News Views 51

The Impressive Growth of SPS Commerce SPS Commerce (NASDAQ: SPSC) has carved out a strong position in the market, consistently providing remarkable returns. Over the last 15 years, this company has outpaced average market growth by a staggering 13.26% each year, resulting in an average annual return of 25.11%. As of now, SPS Commerce enjoys a robust market capitalization...

Continue Reading
Dollar Tree Adjusts Annual Forecast Amid Weak Demand Challenges

Updated Category News Views 66

Dollar Tree Updates Its Annual Forecasts Dollar Tree (NASDAQ: DLTR), a prominent discount store operator, has recently revised its annual forecasts due to a notable drop in demand from budget-conscious shoppers. This change comes as the company struggles to attract customers to its higher-margin products amidst ongoing inflationary challenges. Following this announcement,...

Continue Reading
Join the Class Action Against PepGen Inc. with Confidence

Updated Category News Views 96

Take Action: Class Action Against PepGen Inc. The Gross Law Firm has initiated an important opportunity for shareholders of PepGen Inc. (NASDAQ: PEPG) to participate in a class action lawsuit. If you invested in PepGen during the specific period defined by the firm, it’s essential to be aware of your rights and options. Understanding the Class Period For shareholders,...

Continue Reading
Air Cargo Market Transformation: Expected Growth Ahead

Updated Category News Views 134

The Future of the Air Cargo Market The global air cargo industry is on the threshold of a significant transformation. Recent analyses indicate a positive trajectory, with the market projected to achieve a remarkable valuation of USD 210.93 billion by a defined future point. This invigorating growth can be ascribed to multiple factors, notably the burgeoning e-commerce...

Continue Reading
Chiesi Global Rare Diseases and Protalix BioTherapeutics Collaborate for Innovative Treatments

Updated Category News Views 176

Chiesi Global Rare Diseases and Protalix BioTherapeutics Collaboration Chiesi Global Rare Diseases, a dedicated wing of the Chiesi Group, has taken substantial steps toward advancing therapies for people affected by rare diseases. Collaborating with Protalix BioTherapeutics, this partnership aims to bring innovative solutions to a segment of the population that often...

Continue Reading